Abstract
During the last decades multidrug resistance (MDR) emerged as main problem in the anti-cancer therapy with cytostatically active agents. Classical as well as recently developed cytostatics develop the phenomenon of loosing activity in former drug-sensitive cells. Although MDR is a multifactorial process, the main obstacle is the expression of multidrug-efflux pumps that lowers the intracellular drug levels. P-glycoprotein (P-gp) is the longest identified efflux pump. As the attempt to overcome MDR by the use of inhibitors of the efflux pump activities turned out as most promising effect, the development of P-gp inhibitors has been a challenge for medicinal chemists. The article reviews the advances in P-gp inhibitor development by focussing on structure-activity relationships in the different compound classes to document improvements. The success has been the reduction of cytotoxic properties. The undesired activities could be much lowered in the case of compound classes that were derived from pharmacologically active drugs. Undesired drug interactions and limited in vivo activities are still a problem.
Keywords: Multidrug resistance, P-gp inhibitor, development
Anti-Cancer Agents in Medicinal Chemistry
Title: Recent Advances in the Development of P-gp Inhibitors
Volume: 9 Issue: 4
Author(s): Christiane Baumert and Andreas Hilgeroth
Affiliation:
Keywords: Multidrug resistance, P-gp inhibitor, development
Abstract: During the last decades multidrug resistance (MDR) emerged as main problem in the anti-cancer therapy with cytostatically active agents. Classical as well as recently developed cytostatics develop the phenomenon of loosing activity in former drug-sensitive cells. Although MDR is a multifactorial process, the main obstacle is the expression of multidrug-efflux pumps that lowers the intracellular drug levels. P-glycoprotein (P-gp) is the longest identified efflux pump. As the attempt to overcome MDR by the use of inhibitors of the efflux pump activities turned out as most promising effect, the development of P-gp inhibitors has been a challenge for medicinal chemists. The article reviews the advances in P-gp inhibitor development by focussing on structure-activity relationships in the different compound classes to document improvements. The success has been the reduction of cytotoxic properties. The undesired activities could be much lowered in the case of compound classes that were derived from pharmacologically active drugs. Undesired drug interactions and limited in vivo activities are still a problem.
Export Options
About this article
Cite this article as:
Baumert Christiane and Hilgeroth Andreas, Recent Advances in the Development of P-gp Inhibitors, Anti-Cancer Agents in Medicinal Chemistry 2009; 9 (4) . https://dx.doi.org/10.2174/1871520610909040415
DOI https://dx.doi.org/10.2174/1871520610909040415 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synergistic Enhancement of Cancer Therapy Using a Combination of Fusion Protein MG7-scFv/SEB and Tumor Necrosis Factor Alpha
Protein & Peptide Letters Preparation of Multifunctional Nanoprobes for Tumor-Targeted Fluorescent Imaging and Therapy
Current Drug Targets Free Radical Attack on Cholesterol: Oxysterols as Markers of Oxidative Stress and as Bioactive Molecules
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Recent Updates on the Association Between Alzheimer’s Disease and Vascular Dementia
Medicinal Chemistry Neurotoxicity by Synthetic Androgen Steroids: Oxidative Stress, Apoptosis, and Neuropathology: A Review
Current Neuropharmacology Drug Delivery Systems for Imaging and Therapy of Parkinson's Disease
Current Neuropharmacology From Polypharmacology to Target Specificity: The Case of PARP Inhibitors
Current Topics in Medicinal Chemistry Regulation of Cell Death and Survival by Resveratrol: Implications for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Selecting the Components for a Safe and Efficient Tuberculosis Subunit Vaccine - Recent Progress and Post-Genomic Insights
Current Pharmaceutical Biotechnology High Therapeutic Potential for Systemic Delivery of a Liposomeconjugated Herpes Simplex Virus
Current Cancer Drug Targets NSCLC Structure-activity Relationship (SAR) Study of Diisothiocyanates for Antiproliferative Activity on A549 Human Non-small Cell Lung Carcinoma (NSCLC)
Letters in Organic Chemistry How Does Pain Induce Negative Emotion? Role of the Bed Nucleus of the Stria Terminalis in Pain-Induced Place Aversion
Current Molecular Medicine Steroid Hormone Binding Receptors: Application of Homology Modeling, Induced Fit Docking, and Molecular Dynamics to Study Structure- Function Relationships
Current Topics in Medicinal Chemistry Complex Inheritance for Susceptibility to Sudden Cardiac Death
Current Pharmaceutical Design Therapeutic Cancer Vaccines
Current Cancer Therapy Reviews PP2A in the Regulation of Cell Motility and Invasion
Current Protein & Peptide Science Recent Advances in the Medicinal Chemistry of α-Aminoboronic Acids, Amine-Carboxyboranes and Their Derivatives
Mini-Reviews in Medicinal Chemistry Immunotherapy in Liver Diseases: A Balance Between Immunity and Tolerance
Current Drug Metabolism Protective Effects of Corticosteroids and Neurosteroids on Cochlear injury
Medicinal Chemistry Novel Anti-Angiogenic Compounds for Application in Tumor Therapy – COP9 Signalosome-Associated Kinases as Possible Targets
Mini-Reviews in Medicinal Chemistry